SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Ocuphire Pharma, Inc. (OCUP) , forward earnings yield 14.25%.
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 7.0
Overall SharesGrow Score: 48/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — OCUP
Valuation Multiples
P/E (TTM)0.0
Forward P/E7.0
PEG RatioN/A
Forward PEG0.00
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.80
Forward EPS (Est.)$0.17
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield14.25%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-20.55 |
$0.00 |
$-9.31M |
- |
| 2017 |
$-44.33 |
$0.00 |
$-25.29M |
- |
| 2018 |
$-20.95 |
$0.00 |
$-14.37M |
- |
| 2019 |
$-10.56 |
$0.00 |
$-7.51M |
- |
| 2020 |
$-6.75 |
$0.00 |
$-31.48M |
- |
| 2021 |
$-3.81 |
$589K |
$-56.53M |
-9598.3% |
| 2022 |
$0.87 |
$39.85M |
$17.89M |
44.9% |
| 2023 |
$-0.46 |
$19.05M |
$-9.99M |
-52.4% |
| 2024 |
$-2.15 |
$0.00 |
$-57.53M |
- |
| 2025 |
$-0.80 |
$0.00 |
$-49.59M |
- |
